Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × INDUSTRY × PT2385 × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 261 Paclitaxel 185 Carboplatin 181 Gemcitabine 151 Cisplatin 129 Cyclophosphamide 127 Docetaxel 123 Nivolumab 117 Bevacizumab 108 Injections 95 fludarabine 87 atezolizumab 81 Pemetrexed 81 Dexamethasone 81 Cetuximab 81 Fluorouracil 73 Irinotecan 68 venetoclax 66 Capecitabine 65 Rituximab 64 Azacitidine 60 130-nm albumin-bound paclitaxel 58 Leucovorin 55 Trastuzumab 51 Lenalidomide 51 Oxaliplatin 50 Ipilimumab 50 Fulvestrant 50 Midazolam 49 durvalumab 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡